The Valley Desk

NCT02209376 · Interventional trial

Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma

Overall registry status Terminated

Phase 1

Conditions Patients With Residual or Reccurent EGFRvIII+ Glioma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov